Patent: 9,388,243
✉ Email this page to a colleague
Summary for Patent: 9,388,243
Title: | Method of target membrane protein depletion |
Abstract: | A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions. |
Inventor(s): | Cheong; Kwang Ho (Seoul, KR), Lee; Seung Hyun (Suwon-si, KR), Cho; Mi Young (Seoul, KR), Koh; Young Jun (Yongin-si, KR), Powei; Lin (Hwaseong-si, KR), Yi; Christina (Seongnam-si, KR), Hwang; Jae Woong (Seoul, KR) |
Assignee: | SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) |
Application Number: | 14/290,447 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,388,243 |
Patent Claims: | see list of patent claims |
Details for Patent 9,388,243
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-05-29 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-05-29 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2033-05-29 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2033-05-29 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2033-05-29 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2033-05-29 |
Eli Lilly And Company | CYRAMZA | ramucirumab | Injection | 125477 | 04/21/2014 | ⤷ Try a Trial | 2033-05-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |